Abstract
Background
Methods
Results
REFERENCES
Table 1.
Total (n=98) | Mild neurologic deficit group (n=61) | Moderate to severe neurologic deficit group (n=37) | P value | |
---|---|---|---|---|
Age (years) | 72.2±9.1 | 70.3±9.5 | 75.2±7.6 | 0.009* |
Male | 64 (65.3) | 40 (65.6) | 24 (64.9) | 1.000 |
Initial NIHSS score | 8.4±7.5 | 3.6±2.6 | 16.4±6.0 | <0.001* |
Location of stroke in left hemisphere | 48 (49.0) | 29 (47.5) | 19 (51.4) | 0.668 |
Posterior circulation infarction† | 16 (16.3) | 13 (21.3) | 3 (8.1) | 0.100 |
Hypertension | 63 (64.3) | 34 (55.7) | 29 (78.4) | 0.030‡ |
Diabetes mellitus | 25 (25.5) | 16 (26.2) | 9 (24.3) | 1.000 |
Smoking | 37 (37.8) | 26 (42.6) | 11 (29.7) | 0.283 |
Previous stroke | 12 (12.2) | 4 (6.6) | 8 (21.6) | 0.052 |
Ischemic heart disease | 19 (19.4) | 9 (14.8) | 10 (27.0) | 0.188 |
Peripheral vascular disease | 2 (2.0) | 1 (1.6) | 1 (2.7) | 1.000 |
CHA2DS2-VASc scores | 3.0±1.8 | 2.6±1.7 | 3.6±1.9 | 0.010‡ |
Body mass index | 23.8±3.5 | 23.7±3.6 | 23.8±3.3 | 0.880 |
History of taking antiplatelet agents | 50 (51.0) | 32 (53.3) | 18 (48.6) | 0.681 |
Statin use | 20 (20.4) | 8 (13.6) | 12 (32.4) | 0.038‡ |
Diagnosed as AF previously | 45 (45.9) | 23 (37.7) | 22 (59.5) | 0.040‡ |
PT INR | 1.1±0.1 | 1.1±0.1 | 1.1±0.1 | 0.200 |
Serum D-dimer (mg/L) | 0.94 (0.08-35.20) | 0.6 (0.08-15.54) | 2.34 (0.27-35.20) | |
25% | 0.42 | 0.36 | 0.74 | |
75% | 2.72 | 1.33 | 4.31 | |
Mean | 1.57±2.59 | 4.38±7.01 | 0.042‡ | |
Troponin I (pg/mL) | 0.026 (0.006-0.558) | 0.017 (0.006-0.371) | 0.05 (0.006-0.558) | |
25% | 0.007 | 0.007 | 0.014 | |
75% | 0.100 | 0.100 | 0.100 | |
Mean | 0.059±0.081 | 0.073±0.100 | 0.482 | |
MDRD-eGFR (mL/min/1.73 m2) | 79.1±28.4 | 76.6±23.5 | 83.1±34.9 | 0.325 |
Left ventricular ejection fraction (%) | 58.0±10.6 | 58.6±11.2 | 57.0±9.4 | 0.548 |
NIHSS, National Institutes of Health Stroke Scale; AF, atrial fibrillation; PT INR, prothrombin time international normalized ratio; MDRD-eGFR, estimated glomerular filtration rate using modification of diet in renal disease.
Values are presented as mean±standard deviation, number (%), or median (range).
Analyses were performed by the independent sample t-test, Fisher’s exact test or χ2 test.
Table 2.
ln D-dimer |
ln Troponin I |
||||
---|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | ||
ln D-dimer <-0.87 (Q1) | Reference | ln Troponin I <-4.96 (Q1) | Reference | ||
-0.87≤ ln D-dimer <-0.06 (Q2) | 9.7 (0.7-130.0) | 0.086 | -4.96≤ ln Troponin I <-3.65 (Q2) | 2.6 (0.5-13.8) | 0.250 |
-0.06≤ ln D-dimer <1.00 (Q3) | 30.1 (1.9-486.2) | 0.017* | -3.65≤ ln Troponin I <-2.30 (Q3) | 6.5 (1.3-32.1) | 0.021* |
1.00≤ ln D-dimer (Q4) | 29.7 (2.0-430.8) | 0.013* | -2.30≤ ln Troponin I (Q4) | 0.7 (0.0-16.9) | 0.849 |
NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; CI, confidence interval.
Analyses were performed with multiple logistic regression tests, controlling for CHA2DS2-VASc risk factors (congestive heart failure, hypertension, age, diabetes, stroke/TIA, vascular disease, and female sex).